19. The Impact of Investigational Purified Microbiome Therapeutic SER-109 on Health-Related Quality of Life (HRQoL) of Patients with Recurrent Clostridioides difficile Infection (rCDI) in ECOSPOR III, a Placebo-Controlled Clinical Trial

BACKGROUND: Following standard of care antibiotics, investigational microbiome therapeutic, SER-109, achieved superiority vs placebo (PBO) at 8 weeks in reducing rCDI in patients with ≥3 prior episodes (12.4% vs 39.8%, respectively; p< 0.001). We evaluated the impact of SER-109 vs PBO on HRQoL wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hohmann, Elizabeth, Feuerstadt, Paul, Oneto, Caterina, Berenson, Charles, Lee, Christine, Pham, Sissi, Zhu, Lei, Reese, Pat Ray, Wu, Henry, Wang, Elaine E, von Moltke, Lisa, Garey, Kevin W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Oral Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643838/
http://dx.doi.org/10.1093/ofid/ofab466.019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643838/
http://dx.doi.org/10.1093/ofid/ofab466.019

Ejemplares similares